Advertisement
Screener

CHINA PHARMA HOLDINGS, INC. (CPHI) Increase (Decrease) in Other Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

CHINA PHARMA HOLDINGS, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities

CHINA PHARMA HOLDINGS, INC. (CPHI) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $176.95 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-14

  • CHINA PHARMA HOLDINGS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $191.21K, a 5.94% increase year-over-year.
  • CHINA PHARMA HOLDINGS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$14.26K.
  • CHINA PHARMA HOLDINGS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $180.49K.
  • CHINA PHARMA HOLDINGS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-03-31 was -$78.81K.
  • CHINA PHARMA HOLDINGS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2020 was -$111.16K.
  • CHINA PHARMA HOLDINGS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2019 was -$1.16M, a 285.36% decline from fiscal 2018.
  • CHINA PHARMA HOLDINGS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2018 was $625.13K.
Period endIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month
2026-06-30$191.21K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$176.95K
10-Q · filed 2026-08-14
2026-03-31-$14.26K
10-Q · filed 2026-05-15
2025-06-30$180.49K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$101.68K
10-Q · filed 2026-08-14
2025-03-31-$78.81K
10-Q · filed 2026-05-15
2020-12-31-$1.50K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30
-$226.63K
derived: sum of 2 quarters · filed 2022-03-30
-$337.37K
derived: sum of 3 quarters · filed 2022-03-30
-$111.16K
10-K · filed 2022-03-30
2020-09-30-$225.13K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$335.87K
derived: sum of 2 quarters · filed 2021-11-12
-$109.66K
10-Q · filed 2021-11-12
-$495.13K
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$110.74K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13
$115.47K
10-Q · filed 2021-08-13
-$270.00K
derived: sum of 3 quarters · filed 2021-08-13
-$261.63K
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31$226.21K
10-Q · filed 2021-05-14
-$159.26K
derived: sum of 2 quarters · filed 2021-05-14
-$150.90K
derived: sum of 3 quarters · filed 2021-05-14
-$605.54K
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31-$385.46K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26
-$377.10K
derived: sum of 2 quarters · filed 2021-03-26
-$831.75K
derived: sum of 3 quarters · filed 2021-03-26
-$1.16M
10-K · filed 2021-03-26
2019-09-30$8.36K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13
-$446.28K
derived: sum of 2 quarters · filed 2020-11-13
-$773.26K
10-Q · filed 2020-11-13
2019-06-30-$454.64K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13
-$781.63K
10-Q · filed 2020-08-13
2019-03-31-$326.98K
10-Q · filed 2020-05-14
2018-12-31$625.13K
10-K · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
NANOVIRICIDES, INC. (NNVC)United States$0.031B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30